Industry Reports
Baxter Provides Updated Financial Outlook for 2016
Positive Sales Mix and Disciplined Expense Management Contribute to Strong First Quarter Performance; Adjusted Earnings Per Share were $0.36; First-quarter GAAP Earnings Per Share were $6.13 World pharma today/Industry reports/-Baxter International Inc reported results for the...
Industry Reports
Johnson & Johnson Reports 2016 First-Quarter Results
Johnson & Johnson announced sales of $17.5 billion for the first quarter of 2016, an increase of 0.6% as compared to the first quarter of 2015. Operational sales results increased 3.9% and the negative impact of currency was 3.3%....
Industry Reports
Boehringer Ingelheim has a successful 2015 financial year with net sales increased by 4.1%
Net sales rise to 14.8 billion euros (currency-adjusted: +4.1 per cent; +11.1 per cent in euro terms) Operating income improves markedly to 2.3 billion euros Key strategic course set for future sustainable business development ...
Industry Reports
Teva to Report First Quarter 2016 Financial Results on May 9, 2016
Teva Pharmaceutical Industries Ltd. announced that it will release its first quarter 2016 financial results on Monday, May 9, 2016 at 7:00 a.m. ET. World pharma today/Industry Reports /- Teva will host a conference call and...
Industry Reports
Teva to Report First Quarter 2016 Financial Results on May 9, 2016
Teva Pharmaceutical Industries Ltd  announced that it will release its first quarter 2016 financial results on Monday, May 9, 2016 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same...
Industry Reports
Lilly To Provide Detailed Update Of Pipeline And R&D Strategy At Upcoming Investment Community Meeting
Eli Lilly and Company announced it will host a meeting for the investment community, including institutional investors, sell-side analysts, ratings agency representatives, and financial and business media. World pharma today/Industry reports/- The meeting will take place...
Industry Reports
INNATE PHARMA IN-LICENSES OREGA BIOTECH’S FIRST-IN-CLASS ANTI-CD39 CHECKPOINT INHIBITOR PROGRAM
This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the adenosine immunosuppressive pathway has potential to promote anti-tumor immune responses across a wide range of tumors; Anti-CD39 broadens Innate Pharma’s portfolio of innovative immuno-oncology...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
